101 related articles for article (PubMed ID: 18602957)
1. Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17.
Fiorentini S; Marsico S; Becker PD; Iaria ML; Bruno R; Guzmán CA; Caruso A
Vaccine; 2008 Aug; 26(36):4758-65. PubMed ID: 18602957
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
3. Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study.
Iaria ML; Fiorentini S; Focà E; Zicari S; Giagulli C; Caccuri F; Francisci D; Di Perri G; Castelli F; Baldelli F; Caruso A
Vaccine; 2014 Feb; 32(9):1072-8. PubMed ID: 24456624
[TBL] [Abstract][Full Text] [Related]
4. Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17.
Zimmerman DH; Ulrich JT; Wright C; Lloyd JP; Winship MD; Sarin PS
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):741-9. PubMed ID: 9643374
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
[TBL] [Abstract][Full Text] [Related]
6. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
7. Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag.
de Goede AL; Boers PH; Dekker LJ; Osterhaus AD; Gruters RA; Rimmelzwaan GF
Vaccine; 2009 Sep; 27(42):5735-9. PubMed ID: 19647812
[TBL] [Abstract][Full Text] [Related]
8. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
Tian H; Xiao Y; Qin L; Chen YH
Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
[TBL] [Abstract][Full Text] [Related]
9. Long-lasting humoral immune response induced in HIV-1-infected patients by a synthetic peptide (AT20) derived from the HIV-1 matrix protein p17 functional epitope.
Focà E; Iaria ML; Caccuri F; Fiorentini S; Motta D; Giagulli C; Castelli F; Caruso A
HIV Clin Trials; 2015 Aug; 16(4):157-62. PubMed ID: 26057863
[TBL] [Abstract][Full Text] [Related]
10. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12.
Karpenko LI; Scherbakova NS; Chikaev AN; Tumanova OY; Lebedev LR; Shalamova LA; Pyankova OG; Ryzhikov AB; Ilyichev AA
Mol Immunol; 2012 Apr; 50(4):193-9. PubMed ID: 22341130
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.
Sarin PS; Mora CA; Naylor PH; Markham R; Schwartz D; Kahn J; Heseltine P; Gazzard B; Youle M; Rios A
Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):401-7. PubMed ID: 7580834
[TBL] [Abstract][Full Text] [Related]
12. Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain.
Zimmerman DH; Lloyd JP; Heisey D; Winship MD; Siwek M; Talor E; Sarin PS
Vaccine; 2001 Sep; 19(32):4750-9. PubMed ID: 11535326
[TBL] [Abstract][Full Text] [Related]
13. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting.
Goldstein G; Chicca JJ
Vaccine; 2010 Jan; 28(4):1008-14. PubMed ID: 19931501
[TBL] [Abstract][Full Text] [Related]
14. Pairwise decomposition of residue interaction energies of single chain Fv with HIV-1 p17 epitope variants.
Lee VS; Tue-ngeun P; Nangola S; Kitidee K; Jitonnom J; Nimmanpipug P; Jiranusornkul S; Tayapiwatana C
Mol Immunol; 2010 Feb; 47(5):982-90. PubMed ID: 20022377
[TBL] [Abstract][Full Text] [Related]
15. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLH.
Naylor PH; Sztein MB; Wada S; Maurer S; Holterman D; Kirkley JE; Naylor CW; Zook BC; Hitzelberg RA; Gibbs CJ
Int J Immunopharmacol; 1991; 13 Suppl 1():117-27. PubMed ID: 1823903
[TBL] [Abstract][Full Text] [Related]
17. The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant.
Becker PD; Fiorentini S; Link C; Tosti G; Ebensen T; Caruso A; Guzmán CA
Vaccine; 2006 Jun; 24(25):5269-76. PubMed ID: 16713032
[TBL] [Abstract][Full Text] [Related]
18. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
Lottersberger J; Salvetti JL; Beltramini LM; Tonarelli G
Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866
[TBL] [Abstract][Full Text] [Related]
19. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
